These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 27716258)

  • 21. Clinical assessment of disease activity for canine inflammatory bowel disease.
    Jergens AE
    J Am Anim Hosp Assoc; 2004; 40(6):437-45. PubMed ID: 15533963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic levels of the anti-inflammatory decoy receptor soluble RAGE (receptor for advanced glycation end products) are decreased in dogs with inflammatory bowel disease.
    Heilmann RM; Otoni CC; Jergens AE; Grützner N; Suchodolski JS; Steiner JM
    Vet Immunol Immunopathol; 2014 Oct; 161(3-4):184-92. PubMed ID: 25183017
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized, open-label, positively-controlled field trial of a hydrolyzed protein diet in dogs with chronic small bowel enteropathy.
    Mandigers PJ; Biourge V; van den Ingh TS; Ankringa N; German AJ
    J Vet Intern Med; 2010; 24(6):1350-7. PubMed ID: 21054541
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole.
    Lauritano EC; Gabrielli M; Scarpellini E; Ojetti V; Roccarina D; Villita A; Fiore E; Flore R; Santoliquido A; Tondi P; Gasbarrini G; Ghirlanda G; Gasbarrini A
    Eur Rev Med Pharmacol Sci; 2009; 13(2):111-6. PubMed ID: 19499846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin.
    Prantera C; Lochs H; Campieri M; Scribano ML; Sturniolo GC; Castiglione F; Cottone M
    Aliment Pharmacol Ther; 2006 Apr; 23(8):1117-25. PubMed ID: 16611272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test.
    Low K; Hwang L; Hua J; Zhu A; Morales W; Pimentel M
    J Clin Gastroenterol; 2010 Sep; 44(8):547-50. PubMed ID: 19996983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of ultrasonographic findings with clinical activity index (CIBDAI) and diagnosis in dogs with chronic enteropathies.
    Gaschen L; Kircher P; Stüssi A; Allenspach K; Gaschen F; Doherr M; Gröne A
    Vet Radiol Ultrasound; 2008; 49(1):56-64. PubMed ID: 18251296
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does canine inflammatory bowel disease influence gut microbial profile and host metabolism?
    Xu J; Verbrugghe A; Lourenço M; Janssens GP; Liu DJ; Van de Wiele T; Eeckhaut V; Van Immerseel F; Van de Maele I; Niu Y; Bosch G; Junius G; Wuyts B; Hesta M
    BMC Vet Res; 2016 Jun; 12(1):114. PubMed ID: 27306031
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn's disease.
    Lopetuso LR; Napoli M; Rizzatti G; Gasbarrini A
    Expert Opin Investig Drugs; 2018 Jun; 27(6):543-551. PubMed ID: 29865875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of rifaximin in prevention of diarrhoea in individuals travelling to south and southeast Asia: a randomised, double-blind, placebo-controlled, phase 3 trial.
    Zanger P; Nurjadi D; Gabor J; Gaile M; Kremsner PG
    Lancet Infect Dis; 2013 Nov; 13(11):946-54. PubMed ID: 24012319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibiotic-responsive histiocytic ulcerative colitis in 9 dogs.
    Hostutler RA; Luria BJ; Johnson SE; Weisbrode SE; Sherding RG; Jaeger JQ; Guilford WG
    J Vet Intern Med; 2004; 18(4):499-504. PubMed ID: 15320587
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma amino acid profiles in dogs with inflammatory bowel disease.
    Tamura Y; Ohta H; Kagawa Y; Osuga T; Morishita K; Sasaki N; Takiguchi M
    J Vet Intern Med; 2019 Jul; 33(4):1602-1607. PubMed ID: 31111561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective evaluation of a change in dietary therapy in dogs with steroid-resistant protein-losing enteropathy.
    Wennogle SA; Stockman J; Webb CB
    J Small Anim Pract; 2021 Sep; 62(9):756-764. PubMed ID: 33851420
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of allogeneic adipose tissue-derived mesenchymal stem cells for treatment of dogs with inflammatory bowel disease: Endoscopic and histological outcomes.
    Pérez-Merino EM; Usón-Casaús JM; Duque-Carrasco J; Zaragoza-Bayle C; Mariñas-Pardo L; Hermida-Prieto M; Vilafranca-Compte M; Barrera-Chacón R; Gualtieri M
    Vet J; 2015 Dec; 206(3):391-7. PubMed ID: 26526521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Platelet indices as biomarkers for characterization and determination of severity in canine chronic enteropathy.
    Mehain SO; Haines JM; Lee PM
    Vet J; 2019 Jun; 248():37-41. PubMed ID: 31113560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rifaximin versus metronidazole in management of acute episode of hepatic encephalopathy: An open labeled randomized clinical trial.
    Mekky MA; Riad AR; Gaber MA; Abdel-Malek MO; Swifee YM
    Arab J Gastroenterol; 2018 Jun; 19(2):76-79. PubMed ID: 29935863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth.
    Scarpellini E; Gabrielli M; Lauritano CE; Lupascu A; Merra G; Cammarota G; Cazzato IA; Gasbarrini G; Gasbarrini A
    Aliment Pharmacol Ther; 2007 Apr; 25(7):781-6. PubMed ID: 17373916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of a structured exercise programme in sedentary dogs with chronic diarrhoea.
    Huang HP; Lien YH
    Vet Rec; 2017 Mar; 180(9):224. PubMed ID: 27941060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of once a day rifaximin to twice a day dosage in the prevention of recurrence of hepatic encephalopathy in patients with chronic liver disease.
    Khokhar N; Qureshi MO; Ahmad S; Ahmad A; Khan HH; Shafqat F; Salih M
    J Gastroenterol Hepatol; 2015 Sep; 30(9):1420-2. PubMed ID: 25867912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlating Gastrointestinal Histopathologic Changes to Clinical Disease Activity in Dogs With Idiopathic Inflammatory Bowel Disease.
    Allenspach KA; Mochel JP; Du Y; Priestnall SL; Moore F; Slayter M; Rodrigues A; Ackermann M; Krockenberger M; Mansell J; ; Luckschander N; Wang C; Suchodolski J; Berghoff N; Jergens AE
    Vet Pathol; 2019 May; 56(3):435-443. PubMed ID: 30563436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.